| Original language | English |
|---|---|
| Pages (from-to) | 1813-1814 |
| Number of pages | 2 |
| Journal | The Lancet |
| Volume | 390 |
| Issue number | 10105 |
| DOIs |
|
| Publication status | Published - 21 Oct 2017 |
Cite this
Jenkins, B. J. (2017). Potential efficacy of interleukin-1β inhibition in lung cancer. The Lancet, 390(10105), 1813-1814. https://doi.org/10.1016/S0140-6736(17)32289-4
@article{51f427dcd1a145beb20b343cdef9a660,
title = "Potential efficacy of interleukin-1β inhibition in lung cancer",
author = "Jenkins, {Brendan J.}",
year = "2017",
month = "10",
day = "21",
doi = "10.1016/S0140-6736(17)32289-4",
language = "English",
volume = "390",
pages = "1813--1814",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10105",
}
Jenkins, BJ 2017, 'Potential efficacy of interleukin-1β inhibition in lung cancer', The Lancet, vol. 390, no. 10105, pp. 1813-1814. https://doi.org/10.1016/S0140-6736(17)32289-4
Potential efficacy of interleukin-1β inhibition in lung cancer. / Jenkins, Brendan J.
In: The Lancet, Vol. 390, No. 10105, 21.10.2017, p. 1813-1814.Research output: Contribution to journal › Comment / Debate › Other › peer-review
TY - JOUR
T1 - Potential efficacy of interleukin-1β inhibition in lung cancer
AU - Jenkins, Brendan J.
PY - 2017/10/21
Y1 - 2017/10/21
UR - http://www.scopus.com/inward/record.url?scp=85028323441&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)32289-4
DO - 10.1016/S0140-6736(17)32289-4
M3 - Comment / Debate
VL - 390
SP - 1813
EP - 1814
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10105
ER -
Jenkins BJ. Potential efficacy of interleukin-1β inhibition in lung cancer. The Lancet. 2017 Oct 21;390(10105):1813-1814. https://doi.org/10.1016/S0140-6736(17)32289-4